Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 17/20 | 0.63 |
| ▸ | CTSS | P25774 | 5/20 | 0.47 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.40 |
| ▸ | CTSV | O60911 | 2/20 | 0.39 |
| ▸ | CTSL | P07711 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4042437 | 0.95 | CTSK (0.61) | CTSKCTSSCTSVCTSL | |
| SCHEMBL4043353 | 0.94 | CTSK (0.64) | CTSKCTSSCTSL | |
| SCHEMBL4043134 | 0.94 | CTSK (0.60) | CTSKCTSSCTSVCTSL | |
| SCHEMBL4038274 | 0.90 | CTSK (0.65) | CTSKCTSSCTSVCTSL | |
| SCHEMBL4041441 | 0.89 | CTSK (0.79) | CTSKCTSSCTSVCTSL | |
| SCHEMBL4039281 | 0.89 | CTSK (0.79) | CTSKCTSSCTSVCTSL | |
| SCHEMBL5942356 | 0.89 | CTSK (0.79) | CTSKCTSSCTSVCTSL | |
| SCHEMBL5942351 | 0.89 | CTSK (0.79) | CTSKCTSSCTSVCTSL | |
| SCHEMBL4366565 | 0.88 | CTSK (0.80) | CTSKCTSSSMYD3CTSVCTSL | |
| SCHEMBL5941951 | 0.88 | CTSK (0.80) | CTSKCTSSSMYD3CTSVCTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1603866-B1 | A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE | CADILA HEALTHCARE LTD (IN) | 2009-04-29 | — | — | EP | claimed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | claimed |
| US-20060173214-A1 | Process for the preparation of enantiomerically pure (r) or (s)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide | CADILA HEALTHCARE LIMITED (IN) | 2006-08-03 | — | — | US | claimed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | claimed |
| EP-1603866-A1 | A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE | CADILA HEALTHCARE LTD. (IN) | 2005-12-14 | — | — | EP | claimed |
| EP-1546150-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | Amura Therapeutics Limited (GB) | 2005-06-29 | — | — | EP | claimed |
| WO-2004058694-A1 | A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE | CADILA HEALTHCARE LIMITED (IN) | 2004-07-15 | — | — | WO | claimed |
| WO-2004007501-A1 | BIOLOGICALLY ACTIVE COMPOUNDS | AMURA THERAPEUTICS LIMITED (GB) | 2004-01-22 | — | — | WO | claimed |
| WO-2012101648-A1 | NOVEL PROCESS FOR THE SYNTHESIS OF ENANTIOMERICALLY PURE 2-METHOXY-5-[(2R)-2-(4-ALKYLPIPERAZIN-L-YL)PROPYL]-BENZENESULFONAMIDE | HAVALDAR FREDDY H | 2012-08-02 | — | — | WO | disclosed |
| EP-1603866-B1 | A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE | CADILA HEALTHCARE LTD (IN) | 2009-04-29 | — | — | EP | disclosed |
| EP-1603866-B1 | A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE | CADILA HEALTHCARE LTD (IN) | 2009-04-29 | — | — | EP | disclosed |
| EP-1546150-B1 | PYRROLE DERIVATIVES AS INHIBITORS OF CYTEINE PROTEASES | AMURA THERAPEUTICS LTD (GB) | 2009-03-04 | — | — | EP | disclosed |
| EP-1720830-A1 | PROCESS FOR MANUFACTURING OPTICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENE SULFONAMIDE | CADILA HEALTHCARE LTD. (IN) | 2006-11-15 | — | — | EP | disclosed |
| US-20060173214-A1 | Process for the preparation of enantiomerically pure (r) or (s)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide | CADILA HEALTHCARE LIMITED (IN) | 2006-08-03 | — | — | US | disclosed |
| US-20060100431-A1 | Biologically active compounds | AMURA THERAPEUTICS LIMITED (GB) | 2006-05-11 | — | — | US | disclosed |
| EP-1603866-A1 | A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE | CADILA HEALTHCARE LTD. (IN) | 2005-12-14 | — | — | EP | disclosed |
| EP-1603866-A1 | A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE | CADILA HEALTHCARE LTD. (IN) | 2005-12-14 | — | — | EP | disclosed |
| WO-2005080323-A1 | PROCESS FOR MANUFACTURING OPTICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENE SULFONAMIDE | CADILA HEALTHCARE LIMITED (IN) | 2005-09-01 | — | — | WO | disclosed |
| WO-2004058694-A1 | A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE | CADILA HEALTHCARE LIMITED (IN) | 2004-07-15 | — | — | WO | disclosed |
| WO-2004058694-A1 | A PROCESS FOR THE PREPARATION OF ENANTIOMERICALLY PURE (R) OR (S)-5-(2-AMINOPROPYL)-2-METHOXYBENZENESULFONAMIDE | CADILA HEALTHCARE LIMITED (IN) | 2004-07-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060173214-A1 | Process for the preparation of enantiomerically pure (r) or (s)-5-(2-aminopropyl)-2-methoxybenzenesulfonamide | SRMS, SPR, SRR | CTSK 2447/4885CTSS 175/4885SMYD3 1666/4885 |
| US-20060100431-A1 | Biologically active compounds | SOST, CTSK, CTSS | CTSK 2/4885CTSS 3/4885SMYD3 4011/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.